A new oral investigational treatment option may help you manage your generalized myasthenia gravis symptoms.

See if you may qualify

The ExpanD Study is a clinical research study evaluating an oral investigational medication, ALXN2050, that may help patients manage their generalized myasthenia gravis (gMG) symptoms.

To learn more and to see if you may qualify, talk to your doctor or click the link below.

Learn more about the ExpanD Study.

Reimbursement for travel may be available.